Literature DB >> 6480828

Complement depletion accelerates the clearance of immune complexes from the circulation of primates.

F J Waxman, L A Hebert, J B Cornacoff, M E VanAman, W L Smead, E H Kraut, D J Birmingham, J M Taguiam.   

Abstract

Binding of immune complexes (IC) to erythrocytes in vitro is the result of interaction between C3b sites on the IC, and complement receptors type I (CRI) expressed on primate erythrocytes. Recent evidence indicates that primate erythrocytes can also rapidly bind large, preformed IC in vivo. This study was undertaken to determine if the binding of IC to baboon erythrocytes in vivo is complement dependent and to examine the effect of complement depletion on IC clearance from the circulation. The results indicate that complement depletion in vivo reduced the binding of IC to erythrocytes. There was relatively little binding of IC to leukocytes in both the complement-depleted and complement-repleted condition. Thus, the majority of IC not bound to erythrocytes remained free in the plasma and, consequently, IC infusion during the complement-depleted state resulted in increased plasma IC concentrations. This was associated with a rapid disappearance of IC from the circulation. By contrast, in the normal or complement-repleted state, a large fraction of the IC became bound to erythrocytes during IC infusion, which resulted in lower plasma IC concentrations. Under these conditions, a more gradual rate of disappearance of IC from the circulation was observed. The relatively abrupt clearance of IC from the circulation in the complement-depleted state could not be accounted for by increased hepatic or splenic uptake. These data indicate that, in contrast to previous studies in nonprimates, complement depletion in primates results in accelerated removal of IC from the circulation. This suggests that factors such as hypocomplementemia and deficient expression of erythrocyte CRI, which are known to occur in certain IC-mediated diseases, may promote IC uptake by organs vulnerable to IC-mediated injury.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6480828      PMCID: PMC425300          DOI: 10.1172/JCI111543

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  37 in total

1.  Heterogeneity of the clinical syndrome in patients with systemic lupus erythematosus and genetic deficiency of the second complement component.

Authors:  R I Rynes; R E Urizar; R J Pickering
Journal:  Clin Exp Immunol       Date:  1978-04       Impact factor: 4.330

Review 2.  Molecular biology and chemistry of the alternative pathway of complement.

Authors:  H J Müller-Eberhard; R D Schreiber
Journal:  Adv Immunol       Date:  1980       Impact factor: 3.543

3.  Some hemodynamic determinants of immune complex trapping by the kidney.

Authors:  L A Hebert; C L Allhiser; S M Koethe
Journal:  Kidney Int       Date:  1978-11       Impact factor: 10.612

4.  In vivo generation and clearance of soluble immune complexes containing IgM antibodies in normal and decomplemented rabbits.

Authors:  D L Brown; G D Harkiss
Journal:  Clin Exp Immunol       Date:  1981-02       Impact factor: 4.330

5.  Clearance and tissue uptake of immune complexes in complement-depleted and control mice.

Authors:  B Bockow; M Mannik
Journal:  Immunology       Date:  1981-04       Impact factor: 7.397

6.  The effect of continuous normalization of serum hemolytic complement on the course of lupus nephritis: a five year prospective study.

Authors:  M P Jarrett; L B Sablay; L Walter; P Barland; A I Grayzel
Journal:  Am J Med       Date:  1981-05       Impact factor: 4.965

7.  The significance of serial measurements of serum complement C3 and C4 components and DNA binding capacity in patients with lupus nephritis.

Authors:  E H Garin; W H Donnelly; S T Shulman; R Fernandez; C Finton; R L Williams; G A Richard
Journal:  Clin Nephrol       Date:  1979-10       Impact factor: 0.975

8.  Mononuclear phagocytic system stimulation. Protective role from glomerular immune complex deposition.

Authors:  L Raij; R K Sibley; W F Keane
Journal:  J Lab Clin Med       Date:  1981-10

9.  Clearance kinetics of soluble pre-formed immune complexes containing IgM antibodies in normal and decomplemented rabbits.

Authors:  G D Harkiss; D L Brown
Journal:  Immunology       Date:  1981-02       Impact factor: 7.397

10.  Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase.

Authors:  M D Kazatchkine; D T Fearon; D D Metcalfe; R D Rosenberg; K F Austen
Journal:  J Clin Invest       Date:  1981-01       Impact factor: 14.808

View more
  31 in total

1.  Consumption of erythrocyte CR1 (CD35) is associated with protection against systemic lupus erythematosus renal flare.

Authors:  D J Birmingham; K F Gavit; S M McCarty; C Y Yu; B H Rovin; H N Nagaraja; L A Hebert
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

2.  Immune adherence of nascent hepatitis B surface antigen-antibody complexes in vivo in humans.

Authors:  N Madi; J P Paccaud; G Steiger; J A Schifferli
Journal:  Clin Exp Immunol       Date:  1989-11       Impact factor: 4.330

3.  Elimination of soluble 123I-labelled aggregates of human immunoglobulin G in humans; the effect of splenectomy.

Authors:  C Halma; M R Daha; R van Furth; J A Camps; J H Evers-Schouten; E K Pauwels; S Lobatto; L A Van Es
Journal:  Clin Exp Immunol       Date:  1989-07       Impact factor: 4.330

4.  Immune complexes and erythrocyte CR1 (complement receptor type 1): effect of CR1 numbers on binding and release reactions.

Authors:  Y C Ng; J A Schifferli; M J Walport
Journal:  Clin Exp Immunol       Date:  1988-03       Impact factor: 4.330

5.  Differential complement activation pathways promote C3b deposition on native and acetylated LDL thereby inducing lipoprotein binding to the complement receptor 1.

Authors:  Boudewijn Klop; Pieter van der Pol; Robin van Bruggen; Yanan Wang; Marijke A de Vries; Selvetta van Santen; Joseph O'Flynn; Gert-Jan M van de Geijn; Tjin L Njo; Hans W Janssen; Peter de Man; J Wouter Jukema; Ton J Rabelink; Patrick C N Rensen; Cees van Kooten; Manuel Castro Cabezas
Journal:  J Biol Chem       Date:  2014-10-27       Impact factor: 5.157

6.  Immune complex processing in C1q-deficient mice.

Authors:  J T Nash; P R Taylor; M Botto; P J Norsworthy; K A Davies; M J Walport
Journal:  Clin Exp Immunol       Date:  2001-02       Impact factor: 4.330

7.  Formation of soluble immune complexes by complement in sera of patients with various hypocomplementemic states. Difference between inhibition of immune precipitation and solubilization.

Authors:  J A Schifferli; G Steiger; G Hauptmann; P J Spaeth; A G Sjöholm
Journal:  J Clin Invest       Date:  1985-12       Impact factor: 14.808

Review 8.  Complement activation and complement receptors in systemic lupus erythematosus.

Authors:  J P Atkinson
Journal:  Springer Semin Immunopathol       Date:  1986

9.  Increased frequency of the long (S) allotype of CR1 (the C3b/C4b receptor, CD35) in patients with systemic lupus erythematosus.

Authors:  P Cornillet; P Gredy; J L Pennaforte; O Meyer; M D Kazatchkine; J H Cohen
Journal:  Clin Exp Immunol       Date:  1992-07       Impact factor: 4.330

10.  Mechanism of transfer of immune complexes from red blood cell CR1 to monocytes.

Authors:  W Emlen; V Carl; G Burdick
Journal:  Clin Exp Immunol       Date:  1992-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.